News and Comments

BIOTECHNOLOGY PROMISES A HUGE GROWTH

  Wednesday, December 21, 2011

EXELIXIS’ (EXEL) advanced PI3K-delta research and development preclinical program attracted Merck, known as MSD outside of the United States and Canada. “PI3K-delta is therapeutic target that academic researchers and the drug industry are racing to develop therapeutic antagonists for both inflammatory diseases and cancer. To get to Exelixis program, Merck agreed to pay $12 million in upfront payment in addition to potential milestone payments for multiple indications of up to $239 million and royalties on net-sales of products that would emerge from the agreement. Merck will also pay Exelixis royalties on any compounds that would emerge from Exelixis’ PI3K-delta program or from certain compounds that arise from Merck’s internal discovery efforts targeting PI3K-delta during a certain period. More...


Recent Postings


Archive


Tags

Multiple Myeloma Trastuzumab-DM1 Human Genome Sciences (HGSI) Vertex (VRTX) SYNTA (SNTA) Editas (EDIT) AstraZeneca (AZN) Ionis (IONS) Jazz Pharmaceuticals (JAZZ) Roche (ROCHE) GUARDIAN HEALTH Auspex (ASPX) Human Longevity (HLI) Abbott Laboratories (ABT) Idenix (IDIX) Telaprevir Sanofi (SNY) Seattle Genetics (SGEN) ABBVIE (ABBV) NOVOCURE (NVCR) CompuGen (CGEN) KERYX (KERX) ImmunoGen (IMGN) Spike Therapeutics (ONCE) REGULUS (RGLS) Intrexon (XON) Revlimid (lenolidamide) Merck (MRK) Global Cell Therapeutics (GBT) KITE (KITE) Inovio (INO) Intermune (ITMN) Sangamo (SGMO) Theravance (THRX) Roche (RHHBY) Pluristem (PSTI) Dynavax (DVAX) VANDA (VNDA) Xoma (XOMA) ADVENTRIX (ANX) HALOZYME (HALO) Illumina (ILMN) Elan (ELN) Onyx (ONXX) NEKTAR (NKTR)) Sanofi-Aventis (SAN) JUNO (JUNO) Exelixis (EXEL) Tysabri Sarepta (SRPT) PTC Therapeutics (PTCT) Aimmune Therapeutics (AIMT) IDERA (IDRA) Intercept (ICPT) Velcade (bortezomib) BIOMARIN (BMRN) Valeant Pharmaceuticals International (VRX) Prolor Biotech (PBTH) ZALTRAP™ Gilead (GILD) Ariad (ARIA) INNOVIVA (INVA) Rapamune MODERNA Array Pharmaceuticals (ARRY) Galena (GALE) ISIS (ISIS) Biogen Idec (BIIB) Dendreon (DNDN) Bristol-Myers Squibb (BMY) Zerenex Prosensa (RNA) ACADIA (ACAD) Micromet (MITI) AGOS (ARGS) Mirati Therapeutics (MRTX) Anadys (ANDS) Cytokinetics (CYTK) ARCA (ABIO) C4 Therapeutics RenenxBio (RGNX) NANTKWEST (NK) Alder Biopharmaceuticals (ALDR) Sequenom (SQNM) Alnylam (ALNY) Incyte (INCY) GlaxoSmithKline (GSK) Sanofi (SNA) TOKAI (TKAOI) Vitae Pharmaceuticals (VTAE) SUNESIS PHARMACEUTICALS (SNSS) Biocryst (BCRX) Benlysta (belimumab) Anacor (ANAC) Ziofpharm (ZIOP) Genentech SERES THERAPEUTICS (MCRB) Agenus (AGEN AERIE PHARMACEUTICALS ARGOS (ARGS) Ridaforolimus Endometrial Cancer Agenus (AGEN) Amgen (AMGN) Regeneron (REGN) Herceptin Theravance Bio Pharma (TBPH) galapagos (GLPG) OSI (OSIP)